Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ibrutinib plus venetoclax in mantle cell lymphoma
NL-OMON52949Phase 3Recruiting
- Sponsor
- Pharmacyclics
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ibrutinib and venetoclax in mantle cell lymphoma (MCL) and non-Hodgkin lymphoma (NHL) (4 arms), sponsored by Pharmacyclics. Primary endpoints: Progression-free survival, Complete response rate and 2 more. Started Nov 2018; status: recruiting.
02
Drugs
ibrutinibvenetoclax
03
Conditions
mantle cell lymphoma (MCL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NL-OMON52949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52949.